Literature DB >> 29880442

Arterial lesions in giant cell arteritis: A longitudinal study.

Tanaz A Kermani1, Sehriban Diab2, Antoine G Sreih3, David Cuthbertson4, Renée Borchin4, Simon Carette5, Lindsy Forbess6, Curry L Koening7, Carol A McAlear3, Paul A Monach8, Larry Moreland9, Christian Pagnoux5, Philip Seo10, Robert F Spiera11, Kenneth J Warrington12, Steven R Ytterberg12, Carol A Langford13, Peter A Merkel14, Nader A Khalidi2.   

Abstract

OBJECTIVES: To evaluate large-vessel (LV) abnormalities on serial imaging in patients with giant cell arteritis (GCA) and discern predictors of new lesions.
METHODS: Clinical and imaging data from patients with GCA (including subjects diagnosed by LV imaging) enrolled in a prospective, multicenter, longitudinal study and/or a randomized clinical trial were included. New arterial lesions were defined as a lesion in a previously unaffected artery.
RESULTS: The study included 187 patients with GCA, 146 (78%) female, mean (±SD) age at diagnosis 68.5 ± 8.5 years; 39% diagnosed by LV imaging. At least one arterial lesion was present in 123 (66%) on the first study. The most frequently affected arteries were subclavian (42%), axillary (32%), and thoracic aorta (20%). In 106 patients (57%) with serial imaging, new arterial lesions were noted in 41 patients (39%), all of whom had a baseline abnormality, over a mean (±SD) follow-up of 4.39 (2.22) years. New abnormalities were observed in 33% patients by year 2; clinical features of active disease were present at only 50% of these cases. There were no differences in age, sex, temporal artery biopsy positivity, or disease activity in patients with or without new lesions.
CONCLUSIONS: In this cohort of patients with GCA, LV abnormalities on first imaging were common. Development of new arterial lesions occurred in patients with arterial abnormalities at first imaging, often in the absence of symptoms of active disease. Arterial imaging should be considered in all patients with GCA at diagnosis and serial imaging at least in patients with baseline abnormalities.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Aortic aneurysm; Computed tomography angiography; Disease activity; Giant cell arteritis; Large-artery stenosis; Magnetic resonance angiography

Mesh:

Year:  2018        PMID: 29880442      PMCID: PMC6226363          DOI: 10.1016/j.semarthrit.2018.05.002

Source DB:  PubMed          Journal:  Semin Arthritis Rheum        ISSN: 0049-0172            Impact factor:   5.532


  35 in total

1.  Large vessel involvement in biopsy-proven giant cell arteritis: prospective study in 40 newly diagnosed patients using CT angiography.

Authors:  Sergio Prieto-González; Pedro Arguis; Ana García-Martínez; Georgina Espígol-Frigolé; Itziar Tavera-Bahillo; Montserrat Butjosa; Marcelo Sánchez; José Hernández-Rodríguez; Josep M Grau; Maria C Cid
Journal:  Ann Rheum Dis       Date:  2012-01-20       Impact factor: 19.103

2.  18 F-Fluorodeoxyglucose-Positron Emission Tomography As an Imaging Biomarker in a Prospective, Longitudinal Cohort of Patients With Large Vessel Vasculitis.

Authors:  Peter C Grayson; Sara Alehashemi; Armin A Bagheri; Ali Cahid Civelek; Thomas R Cupps; Mariana J Kaplan; Ashkan A Malayeri; Peter A Merkel; Elaine Novakovich; David A Bluemke; Mark A Ahlman
Journal:  Arthritis Rheumatol       Date:  2018-02-06       Impact factor: 10.995

3.  Long-term follow-up of upper and lower extremity vasculitis related to giant cell arteritis: a series of 36 patients.

Authors:  Cyrielle Assie; Alain Janvresse; Didier Plissonnier; Hervé Levesque; Isabelle Marie
Journal:  Medicine (Baltimore)       Date:  2011-01       Impact factor: 1.889

4.  Lower limb giant cell arteritis and temporal arteritis: followup of 8 cases.

Authors:  C Le Hello; H Lévesque; M Jeanton; N Cailleux; F Galateau; C Peillon; P Veyssier; J Watelet; P Letellier; H Courtois; D Maïza
Journal:  J Rheumatol       Date:  2001-06       Impact factor: 4.666

Review 5.  Update on Outcome Measure Development for Large Vessel Vasculitis: Report from OMERACT 12.

Authors:  Sibel Zehra Aydin; Haner Direskeneli; Antoine Sreih; Fatma Alibaz-Oner; Ahmet Gul; Sevil Kamali; Gulen Hatemi; Tanaz Kermani; Sarah L Mackie; Alfred Mahr; Alexa Meara; Nataliya Milman; Heidi Nugent; Joanna Robson; Gunnar Tomasson; Peter A Merkel
Journal:  J Rheumatol       Date:  2015-06-15       Impact factor: 4.666

6.  Extracranial angiographic findings in giant cell (temporal) arteritis.

Authors:  A W Stanson; R G Klein; G G Hunder
Journal:  AJR Am J Roentgenol       Date:  1976-12       Impact factor: 3.959

7.  Long-term follow-up of aortic involvement in giant cell arteritis: a series of 48 patients.

Authors:  Isabelle Marie; Alice Proux; Pierre Duhaut; Etienne Primard; Laure Lahaxe; Nicolas Girszyn; Jean-Pierre Louvel; Hervé Levesque
Journal:  Medicine (Baltimore)       Date:  2009-05       Impact factor: 1.889

8.  Incidence and predictors of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years.

Authors:  Dirk M Nuenninghoff; Gene G Hunder; Teresa J H Christianson; Robyn L McClelland; Eric L Matteson
Journal:  Arthritis Rheum       Date:  2003-12

9.  Trial of Tocilizumab in Giant-Cell Arteritis.

Authors:  John H Stone; Katie Tuckwell; Sophie Dimonaco; Micki Klearman; Martin Aringer; Daniel Blockmans; Elisabeth Brouwer; Maria C Cid; Bhaskar Dasgupta; Juergen Rech; Carlo Salvarani; Georg Schett; Hendrik Schulze-Koops; Robert Spiera; Sebastian H Unizony; Neil Collinson
Journal:  N Engl J Med       Date:  2017-07-27       Impact factor: 91.245

10.  The relative risk of aortic aneurysm in patients with giant cell arteritis compared with the general population of the UK.

Authors:  Joanna C Robson; Amit Kiran; Joe Maskell; Andrew Hutchings; Nigel Arden; Bhaskar Dasgupta; William Hamilton; Akan Emin; David Culliford; Raashid A Luqmani
Journal:  Ann Rheum Dis       Date:  2013-10-04       Impact factor: 19.103

View more
  7 in total

1.  Incidence of giant cell arteritis in six districts of Paris, France (2015-2017).

Authors:  Solange Gonzalez Chiappe; Sarah Lechtman; Carla Soledad Maldini; Arsène Mekinian; Thomas Papo; Thomas Sené; Alfred Daniel Mahr
Journal:  Rheumatol Int       Date:  2022-07-12       Impact factor: 3.580

Review 2.  Highlights in clinical medicine-Giant cell arteritis, polymyalgia rheumatica and Takayasu's arteritis: pathogenic links and therapeutic implications.

Authors:  Antonio Giovanni Solimando; Angelo Vacca; Franco Dammacco
Journal:  Clin Exp Med       Date:  2021-11-06       Impact factor: 5.057

Review 3.  Pathogenesis, Diagnosis and Management of Polymyalgia Rheumatica.

Authors:  Dario Camellino; Andrea Giusti; Giuseppe Girasole; Gerolamo Bianchi; Christian Dejaco
Journal:  Drugs Aging       Date:  2019-11       Impact factor: 3.923

4.  Comparing Semiquantitative and Qualitative Methods of Vascular 18F-FDG PET Activity Measurement in Large-Vessel Vasculitis.

Authors:  Himanshu R Dashora; Joel S Rosenblum; Kaitlin A Quinn; Hugh Alessi; Elaine Novakovich; Babak Saboury; Mark A Ahlman; Peter C Grayson
Journal:  J Nucl Med       Date:  2021-06-04       Impact factor: 10.057

Review 5.  [Diagnostics and treatment of giant cell arteritis].

Authors:  Markus Kraemer; Jana Becker; Thorsten Alexander Bley; Andreas Steinbrecher; Jens Minnerup; Bernhard Hellmich
Journal:  Nervenarzt       Date:  2021-11-03       Impact factor: 1.297

Review 6.  Spectrum of Large and Medium Vessel Vasculitis in Adults: Primary Vasculitides, Arthritides, Connective Tissue, and Fibroinflammatory Diseases.

Authors:  Luca Seitz; Pascal Seitz; Roxana Pop; Fabian Lötscher
Journal:  Curr Rheumatol Rep       Date:  2022-09-27       Impact factor: 4.686

7.  Associated factors of poor treatment outcomes in patients with giant cell arteritis: clinical implication of large vessel lesions.

Authors:  Takahiko Sugihara; Hitoshi Hasegawa; Haruhito A Uchida; Hajime Yoshifuji; Yoshiko Watanabe; Eisuke Amiya; Yasuhiro Maejima; Masanori Konishi; Yohko Murakawa; Noriyoshi Ogawa; Shunsuke Furuta; Yasuhiro Katsumata; Yoshinori Komagata; Taio Naniwa; Takahiro Okazaki; Yoshiya Tanaka; Tsutomu Takeuchi; Yoshikazu Nakaoka; Yoshihiro Arimura; Masayoshi Harigai; Mitsuaki Isobe
Journal:  Arthritis Res Ther       Date:  2020-04-07       Impact factor: 5.156

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.